Back to Search
RAYMOND COMENZO, MD
MD
Hematology & Oncology Physician
NPI: 1750352787IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
212755(NY)
Hematology (Internal Medicine) Physician
Internal Medicine — Hematology
Code: 207RH0000X
59940(MA)
Education
BOSTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1986
Research & Publications (20)
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
PMID 16319952·Leukemia·2006
3-trial
Autologous stem cell transplantation for primary systemic amyloidosis.
PMID 12036853·Blood·2002
6-review
The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
PMID 11468171·Blood·2001
8-other
Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned.
PMID 10752977·Leuk Lymphoma·2000
6-review
AL amyloidosis and progression to multiple myeloma with gain(1q).
PMID 19120348·Br J Haematol·2009
5-case
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma.
PMID 19421229·Leukemia·2009
6-review
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
PMID 19561323·Blood·2009
8-other
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
PMID 19494840·Leukemia·2009
6-review
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
PMID 19498019·Blood·2009
3-trial
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
PMID 19554029·Leukemia·2009
6-review
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
PMID 19020545·Leukemia·2009
6-review
Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).
PMID 18162215·Biol Blood Marrow Transplant·2008
6-review
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
PMID 18175384·N Engl J Med·2008
8-other
CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy.
PMID 18216299·Blood·2008
7-preclinical
High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
PMID 18574442·Bone Marrow Transplant·2008
8-other
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone.
PMID 18691169·Br J Haematol·2008
3-trial
Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego).
PMID 19122741·Biol Blood Marrow Transplant·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 800 WASHINGTON ST
BOSTON, MA 02111 - Phone
- (617) 636-5000
Quick Facts
- NPI
- 1750352787
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 40
- Publications
- 20
Are you this provider?
Claim Your Profile